Crinetics Pharmaceuticals CRNX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $115.14M+12.5% | $102.34M-8.8% | $112.2M+109% | $53.73M-44.0% | $95.87M-63.9% | ||
| $1.18B+27.1% | $926.35M-5.6% | $981.39M-14.1% | $1.14B-3.1% | $1.18B+8.3% | ||
| $5.68M+860% | $592K— | —— | —— | $0— | ||
| $3.06M+51.5% | $2.02M— | —— | —— | $0— | ||
| $1.32B+26.1% | $1.05B-6.5% | $1.12B-7.9% | $1.22B-5.7% | $1.29B-6.1% | ||
| $13.5M-5.6% | $14.3M-0.6% | $14.38M-2.0% | $14.67M+16.2% | $12.63M+4.6% | ||
| $1.4B+24.4% | $1.13B-5.8% | $1.2B-7.3% | $1.29B-5.3% | $1.36B-5.1% | ||
| $12.88M-43.0% | $22.61M+270% | $6.11M-84.0% | $38.09M+20.5% | $31.62M+440% | ||
| $1.27M+2.9% | $1.24M-24.8% | $1.64M-13.8% | $1.9M-13.7% | $2.21M+1.4% | ||
| $71.09M-16.4% | $85.07M+14.7% | $74.16M+8.4% | $68.4M+19.3% | $57.31M-4.0% | ||
| $120.68M-10.1% | $134.17M+8.3% | $123.86M+4.9% | $118.05M+10.0% | $107.33M-2.2% | ||
| 200M0.0% | 200M0.0% | 200M-91.4% | 2.3B+1.5% | 2.3B+1.1% | ||
| -$1.55B-9.0% | -$1.42B-9.5% | -$1.29B-11.2% | -$1.16B-11.0% | -$1.05B-10.2% | ||
| $1.28B+29.1% | $992.08M-7.5% | $1.07B-8.5% | $1.17B-6.6% | $1.25B-5.3% | ||
| $1.4B+24.4% | $1.13B-5.8% | $1.2B-7.3% | $1.29B-5.3% | $1.36B-5.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Crinetics Pharmaceuticals cover its short-term obligations?
- Its current ratio is 18.60 — current assets exceed current liabilities.
- Where does Crinetics Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.